Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk

Hypercholesterolemia is a major risk factor for cardiovascular disease (CVD). Lowering low-density lipoproteins-cholesterol (LDL-C) has been shown to decrease the risk of CVD and of all-cause mortality. For appropriate management, estimation of each individual’s total cardiovascular risk is critical, as patients should receive treatment according to their cardiovascular risk category as well as their LDL-C level. However, available data indicate that a large proportion of patients fail to achieve lipid goals despite treatment, and a significant percentage of patients are not able to tolerate statin treatment. Researchers have therefore focused considerable attention on the development of novel LDL-C-lowering agents that act via different mechanisms. Among the most recent advances in clinical development are the proprotein convertase subtilisin/kexin 9 antibody inhibitors, including alirocumab and evolocumab, which appear particularly promising, with clinical trial data indicating these agents to be both well tolerated and highly efficacious in lowering LDL-C.

Download Full-text

Dietary Fish Oil Concentrates Associated Health Benefits: A Recent Development of Cardiovascular Risk Reduction

Current Pharmaceutical Design ◽

10.2174/1381612825666191112141320 ◽

2019 ◽

Vol 25 (38) ◽

pp. 4053-4062 ◽

Cited By ~ 1

Author(s):

Sudhanshu S. Behera

Keyword(s):

Fatty Acids ◽

Cardiovascular Risk ◽

Fish Oil ◽

Health Benefits ◽

New Drugs ◽

Omega 3 ◽

High Cardiovascular Risk ◽

Cardiovascular Risk Reduction ◽

Beneficial Effects ◽

Dietary Fish

Fish oil is an abundant source of omega-3 (n-3 or ω-3) polyunsaturated fatty acids (PUFAs) and contains Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA). PUFAs are very effective in preventing/ inhibiting cardiovascular incidents, particularly in individuals with high cardiovascular risk/accidents. In this review, composition, extraction of fish oil and its favorable/beneficial effects in Cardiovascular Diseases (CVDs) and molecular mechanism for its treatment/reduction have been discussed. Moreover, the application of fish oil for preventive/protective and remedial/curative properties in nutritive and health benefits has been summarized. All these aspects further search the opportunities/hope and scope with its expected opening and anticipations/ possibilities to provide additional therapeutic substitutes for the reduction of CVDs and registration of new drugs.

Download Full-text

Hyperuricemia as risk factor for cardiovascular disease – what’s new?

Medical alphabet ◽

10.33667/2078-5631-2020-13-5-11 ◽

2020 ◽

pp. 5-11

Author(s):

Yu. V. Zhernakova

Keyword(s):

Cardiovascular Disease ◽

Chronic Kidney Disease ◽

Uric Acid ◽

Cardiovascular Risk ◽

Epidemiological Studies ◽

Point Of View ◽

Medical Society ◽

High Cardiovascular Risk ◽

Management Algorithm ◽

Russian Medical

A significant number of epidemiological studies have shown that hyperuricemia is highly associated with the risk of developing cardiovascular disease, chronic kidney disease, and diabetes. In this connection, increased attention is required to monitor serum uric acid levels in patients, not only from a rheumatological point of view, but also with regard to reducing cardiovascular and renal risks. This article is a review of studies on the association of hyperuricemia with cardiovascular risk and a new consensus for the management of patients with hyperuricemia and high cardiovascular risk, published in december 2019 by a group of experts of the Russian Medical Society for Arterial Hypertension, which, among other things, includes a management algorithm of this category of patients.

Download Full-text

The effect of PCSK9 Inhibitor EVOLOCUMAB on aldosterone among high cardiovascular risk patients

Endocrine Abstracts ◽

10.1530/endoabs.70.ep124 ◽

2020 ◽

Author(s):

Elena Lzkhakov ◽

Yakov Shacham ◽

Mariana Yaron ◽

Merav Serebro ◽

Karen Tordjman ◽

...

Keyword(s):

Cardiovascular Risk ◽

High Cardiovascular Risk ◽

Pcsk9 Inhibitor ◽

Risk Patients

Download Full-text

Telmisartan in High Cardiovascular Risk Patients

European Cardiology Review ◽

10.15420/ecr.2012.8.1.10 ◽

2012 ◽

Vol 8 (1) ◽

pp. 10 ◽

Cited By ~ 1

Author(s):

Roland Asmar ◽

Keyword(s):

Cardiovascular Disease ◽

Cardiovascular Risk ◽

Ace Inhibitors ◽

Angiotensin Receptor Blockers ◽

High Cardiovascular Risk ◽

Raas Blockade ◽

Risk Patients ◽

Receptor Blockers ◽

Current Guidelines

The worldwide morbidity and mortality burden of cardiovascular disease (CVD) is overwhelming and caused by increasing life expectancy and an epidemic of risk factors, including hypertension. Therapeutic options targeting different areas of the renin–angiotensin–aldosterone system (RAAS) to disrupt pathophysiological processes along the cardiovascular continuum are available. Angiotensin-converting enzyme (ACE) inhibitors are first-line treatments for CVD and angiotensin receptor blockers (ARBs) are suitable alternatives. Both ACE inhibitors and ARBs prevent CVD by lowering blood pressure (BP). Additionally, several studies have demonstrated that RAAS blockade can reduce cardiovascular risk beyond what might be expected from BP lowering alone. However, the ARBs are not all equally effective. Telmisartan is a long-lasting ARB that effectively controls BP over the full 24-hour period. Recently, the Ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET) study showed that telmisartan reduces cardiovascular events in high cardiovascular risk patients similarly to the gold standard ACE inhibitor ramipril beyond BP lowering alone, but with a better tolerability. Based on the results of the ONTARGET and Telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) studies, telmisartan is indicated for the reduction of cardiovascular morbidity. This article aims to review current guidelines for the management of CVD and consider key data from clinical trials and clinical practice evaluating the role of telmisartan in CVD.

Download Full-text